The Valley Desk

Clinical trial reportBreast (Edinburgh, Scotland)Published

Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Bristol Myers Squibb. Affiliation source

Publication record

Type
Clinical trial report
Venue
Breast (Edinburgh, Scotland)
Published
Subject terms
Humans; Breast Neoplasms; Pneumonia; Piperazines; Pyridines; Receptors, Estrogen; Antineoplastic Combined Chemotherapy Protocols; Neoadjuvant Therapy; Female; Anastrozole; Nivolumab; Erb-b2 Receptor Tyrosine Kinases
PubMed ID
37741273
PubMed Central ID
PMC10519837
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal